To retrospectively analyze the safety and efficacy of low dose subcutaneous decitabine regimen in patients with acute myeloid leukemia (AML) and intermediate- or higer-risk myelodysplastic syndrome (MDS). Of 6 AML cases, 2 achieved complete remission (CR), 2 with partial remission(PR), 1 with stable disease(SD), 1 with progressive disease(PD). As to the 8 MDS patients, one achieved CR and 6 with hematologic improvement (HI), 1 case SD. Low dose subcutaneous decitabine regimen could be an alternative choice of older AML or MDS patients.
回顾性分析低剂量地西他滨皮下注射治疗老年急性髓系白血病(AML)及中高危骨髓增生异常综合征(MDS)的安全性及疗效。结果显示所有患者均顺利完成治疗；6例AML中，完全缓解(CR) 2例，部分缓解(PR)且血液学进步(HI) 2例，疾病稳定(SD) 1例，疾病进展(PD) 1例；8例MDS中，CR 1例，骨髓缓解伴血象不完全恢复(CRi)＋HI 4例，HI 2例，SD 1例。对于老年AML及中高危MDS，低剂量地西他滨皮下注射治疗安全、有效。.
Keywords: Decitabine; Injections, subcutaneous; Leukemia; Low dose; Myelodysplastic syndromes.